Brief: Annovis Announces FDA Meeting To Discuss Parkinson's Disease Dementia Program Reaffirms FDA Alignment On Pivotal Phase 3 Alzheimer's Disease Study
18/11/2025 13:17
Annovis Bio Inc ANVS.N: ANNOVIS ANNOUNCES FDA MEETING TO DISCUSS PARKINSON'S DISEASE DEMENTIA PROGRAM; REAFFIRMS FDA ALIGNMENT ON PIVOTAL PHASE 3 ALZHEIMER'S DISEASE STUDY ANNOVIS BIO INC - ANNOUNCES FDA TYPE C MEETING FOR JANUARY 2026 Source text: ID:nGNX9kxr7c Further company coverage: ANVS.N
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman